Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAK2359
- Development stage
- Preclinical
- Lead developer
- MAK Scientific
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MAK2359 is a peripherally restricted, neutral antagonist of the cannabinoid receptor 1 (CB1), currently in preclinical development by MAK Scientific Management. By selectively targeting peripheral CB1 receptors, MAK2359 aims to avoid the neuropsychiatric side effects associated with central CB1 inhibition, which limited the clinical utility of earlier compounds in this class. The drug is being investigated for the treatment of chronic kidney disease (CKD), where it is intended to mitigate renal fibrosis and inflammation driven by overactive endocannabinoid signaling in peripheral tissues.
- Other names
- MAK2359MAK-2359MAK 2359
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MAK2359.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAK2359.